Theralase Technologies Inc. V.TLT

BioWorld Article

[Eoganacht]

Light-activated compound possible answer to non-muscle invasive bladder cancer

July 10, 2023

By David Godkin                 

 

Theralase Technologies Inc. has pioneered technology said to selectively infiltrate and kill non-muscle invasive bladder cancer (NMIBC) at the cellular level. Bladder cancer generally is the 10th most common cancer in the world (6th in men and 17th in women), and gradually showing up in greater numbers in other patient groups.
 

 

That's all you get for free. If you want to read the whole article uou have to subscribe to BioWorld.

 

Subscriptions to BioWorld are $US 4,000.00 per year

If you want BioWorld Premium it's $US 9,000.00 per year

[BlueFranky]

I can see it now.. Roger White... Dons sunglasses and a fedora .. with a slight smile, looks into the camera and says: "Theralase - SAY MY NAME!"

[ScienceFirst]

Nice catch Eoganacht. Possible that it also comes with a presentation at BioFuture early October as BIOWorld and BioFuture go hand in hand. https://biofuture.com/biofuture-presenting-companies/

[CAinPlap]

I will count myself lucky that I don't have to dish out $4K to find out what a great investment TLT could/should be. :)

[Legit62]

Im in!!!!!

[skys1]

Legit, so am I. It certainly appears that compared to a year or two ago, the word about this remarkable science and cancer treatment is finally getting out. Currently finally with some much needed PR, it seems now it is only a matter of time.